Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick McEneaney

Podiatrist, Foot & Ankle Surgery Cary, IL Doctor of Podiatric Medicine

NPI 1174613319 CMS profile 280524

113 W Main St, Cary, IL 60013

Open in the dashboard

General payments

$570,071

520 records reported · program years 2019–2025

Research payments

$21,131

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$213,891

5 holdings reported · through program year 2025

Research they led as principal investigator

$15,495 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Patrick McEneaney of Cary, IL is reported in the CMS Open Payments database as having received $570,071 across 520 general payments and $21,131 in research payments paid to them. Separately, studies naming them as principal investigator received $15,495 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $213,891 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84,764 112
2025 Research $19,550 2
2024 General $139,619 89
2024 Research $1,581 2
2023 General $61,808 65
2022 General $42,560 68
2021 General $140,241 62
2020 General $29,483 46
2019 General $71,595 78
2021 Ownership $31,047 1
2020 Ownership $99,300 2
2019 Ownership $83,544 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick McEneaney
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Patrick McEneaney were reported at $84,764. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Patrick McEneaney Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $71,595 $389 $118–$1,406 $163
2020 $29,483 $191 $62–$691 $114
2021 $140,241 $329 $104–$1,341 $132
2022 $42,560 $419 $125–$1,611 $149
2023 $61,808 $377 $128–$1,164 $160
2024 $139,619 $394 $134–$1,168 $164
2025 $84,764 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $190,715 84 payments
  2. DePuy Synthes Sales Inc. $119,575 26 payments
  3. MedShape, Inc. $115,391 3 payments
  4. Crossroads Extremity Systems, LLC $67,832 20 payments
  5. TissueTech, Inc. $15,143 3 payments
  6. Stryker Corporation $14,341 145 payments
  7. Biocomposites Inc $12,445 27 payments
  8. Innovation Technologies Inc $11,377 8 payments
  9. Synthes USA Products LLC $8,190 4 payments
  10. Surgenex LLC $1,629 15 payments
  11. Other $13,433 185 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $182,428 28 payments
  2. Acquisitions $115,043 1 payment
  3. Compensation for serving as faculty or as a speaker for a medical education program $79,613 16 payments
  4. Consulting Fee $58,959 35 payments
  5. Food and Beverage $34,738 370 payments
  6. Charitable Contribution $25,000 1 payment
  7. Travel and Lodging $20,412 41 payments
  8. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,038 9 payments
  9. Grant $15,000 1 payment
  10. Honoraria $12,500 3 payments
  11. Other $10,341 15 payments
Products named General payments · program years 2019–2025
  1. Kerecis Omega3 SurgiClose $113,944 33 payments
  2. Kerecis Omega3 Marigen Wound Care $111,450 31 payments
  3. Kerecis Omega3 Marigen Wound Care $100,004 26 payments
  4. Kerecis Omega3 Marigen Wound Care $100,004 26 payments
  5. Kerecis Omega3 Marigen Wound Care $100,004 26 payments
  6. MOTOBAND $55,918 12 payments
  7. Kerecis SurgiClose Wound Care $45,666 42 payments
  8. Kerecis GraftGuide $45,666 42 payments
  9. Kerecis SurgiClose Wound Care $45,666 42 payments
  10. Kerecis SurgiClose Wound Care $45,666 42 payments
  11. Other $252,922 600 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Kerecis Limited $19,550 2 payments
  2. Innovation Technologies Inc $1,581 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

95

Median for Podiatry: 160

Drug cost

$833

Median for Podiatry: $2,368

Branded share of claims

23.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 34 $324
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 22 $214
Gabapentin Generic 28 $203
Terbinafine Hcl Generic 11 $93

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$130,218

Of which drugs: $629

Medicare patients

344

Average age 74

Services billed

1,980

186 women, 158 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 39%
Ischemic heart disease 28%
Chronic kidney disease 27%
Atrial fibrillation 20%
Heart failure 18%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 43 110 $590

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record